Long-acting Injectables in Schizophrenia: An Evidence-Based Strategy to Get Your Patients to Remission and RecoveryPremiere Date: Wednesday, September 22, 2021
This activity offers CE credit for:%>
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, September 22, 2022
|John Lauriello, MD (Moderator)
Daniel Lieberman Professor and Chair
Department of Psychiatry and Human Behavior
Senior Vice President of Behavioral Health
Sidney Kimmel Medical College at Thomas Jefferson University
|Deanna L. Kelly, PharmD, BCPP
Professor of Psychiatry
Director, Treatment Research Program (TRP)
Maryland Psychiatric Research Center (MPRC)
University of Maryland School of Medicine
The key goals of schizophrenia therapy are symptom control, relapse prevention, and restoration of function and quality of life. These goals are often impeded by patients’ nonadherence to oral antipsychotics (OAPs). Long-acting injectables (LAIs) are a safe, effective strategy for the management of schizophrenia, demonstrating superiority over OAPs in reducing hospitalization rates, time to hospitalization, recurrent hospitalizations, emergency department visits, and all-cause discontinuations, as well as improving adherence. Despite the 2020 APA Practice Guidelines for the Treatment of Patients with Schizophrenia recommending their use, LAIs are not widely used in the management of schizophrenia, particularly during the early phase of illness.
In this 2nd episode of a three-part CME Outfitters Snack series on schizophrenia, faculty will review the latest clinical evidence on LAIs and provide clinicians with tips for personalizing treatment selection and initiation, considering dose and dosing schedules.
At the end of this CE activity, participants should be able to:
- Formulate practice strategies for the use of LAIs in patients with schizophrenia while considering treatment initiation, dose, and dosing schedules.
Supported by an educational grant from Alkermes
Psychiatrists, psychiatric residents, psychiatric nurses, primary care physicians, PAs, nurse practitioners, and pharmacists
ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC: Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Lauriello reports that he is a consultant for Avanir Pharmaceuticals, Inc. Data Safety Board; Karuna Therapeutics Independent Safety Monitoring Committee (ISMC); and Orexo.
Dr. Kelly reports that she is a consultant for Alkermes; Lyndra Therapeutics, Inc.; and Sunovion Pharmaceuticals Inc.
Kashemi D. Rorie, PhD (planning committee) has no disclosures to report.
Evan Luberger (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).